Application of genipin beta-methyl derivative gen-17 in preparation of drug for prevention and treatment of acute severe pneumonia
An application of a genipin beta-methyl derivative, Gen-17, in a preparation of a drug for prevention and treatment of acute severe pneumonia is provided. A mouse model of acute lung injury (ALI) is first used to simulate acute severe pneumonia of human beings, and preventive and therapeutic effects of the Gen17 on mice with ALI are systematically evaluated. The results show that the Gen17 can significantly alleviate pathomorphological damage of lung tissues of ALI mice induced by lipopolysaccharide, and inhibit inflammatory reaction and oxidative stress of the lung tissues. A protective mechanism of the Gen-17 on the lung of the ALI mice is that an anti-inflammatory role is played by inhibiting NF-κB and MAPK signaling pathways, and an anti-oxidative role is played by activating Keap1/Nrf2/HO-1 signaling pathways. It can provide some experimental basis for the application of the Gen-17 in prevention and treatment of acute severe pneumonia.
1 . A method for treating acute severe pneumonia, comprising:
administering to a subject a therapeutically effective amount of a compound Gen-17 having the following chemical structure:
2 . The method as claimed in claim 1 , wherein the therapeutically effective amount is in a range of 12.5 milligrams per kilogram (mg/kg) to 50 mg/kg of body weight per day.
3 . The method as claimed in claim 1 , wherein the compound Gen-17 is used to inhibit nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways in lung tissue of the subject.
4 . The method as claimed in claim 1 , wherein the compound Gen-17 is used to activate Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2)/heme Oxygenase-1 (HO-1) signaling pathways in lung tissue of the subject.